The present disclosure relates to erythroid cells that have been engineered to express a homocysteine reducing polypeptide, or a variant thereof, or a homocysteine degrading polypeptide, or a variant thereof. The engineered erythroid cells may further comprise an amino acid transporter, for example a homocysteine transporter or a serine transporter, or a cystathionine degrading polypeptide. The engineered erythroid cells of the present disclosure are useful in reducing the level of homocysteine in a subject. The engineered erythroid cells of the present disclosure are further useful in methods of treating homocystinuria.
